Mitomycin C plus capecitabine (MiXe) in anthracycline- and taxane-pretreated metastatic breast cancer. A multicenter phase II study

Roberto Maisano, Nicola Caristi, Marzia Mare, Mario Raffaele, Monica Iorfida, Antonino Mafodda, Maria Zavettieri, Mario Nardi

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Capecitabine is considered the treatment of choice for anthracycline- and taxane-pretreated metastatic breast cancer. Mitomycin C seems to improve the activity of capecitabine by up-regulation of thymidine phosphorylase. Patients and Methods: Fifty-five women with metastatic breast cancer previously treated with anthracycline-taxane were treated with mitomycin C 10 mg/m 2 on day 1 every six weeks and capecitabine 1000 mg/m 2 on days 2-15 every three weeks. Results: An overall response rate of 38% was found, consisting of 3 (5%) complete responses (CR) and 18 (33%) partial responses (PR); 8 patients (14%) had a stable disease (SD) for more than 4 months. The combination was well-tolerated, with the main toxicities being neutropenia, diarrhea and fatigue; other toxicities were of mild to moderate intensity without impairment in the quality of life of the patients. Conclusion: Capecitabine is confirmed as the drug of choice in the treatment of anthracycline- and taxane-pretreated metastatic breast cancer and its combination with mitomycin appears to improve its efficacy.

Original languageEnglish
Pages (from-to)2871-2875
Number of pages5
JournalAnticancer Research
Volume27
Issue number4 C
Publication statusPublished - Jul 2007

Keywords

  • Capecitabine
  • Metastatic breast cancer
  • Mitomycin C

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Mitomycin C plus capecitabine (MiXe) in anthracycline- and taxane-pretreated metastatic breast cancer. A multicenter phase II study'. Together they form a unique fingerprint.

Cite this